This application relates generally to the field of intraocular devices. More particularly, this application is directed to intraocular implants and lenses (IOLs) with an aperture to increase depth of focus (e.g. “masked” intraocular lenses), and methods of making the same.
The human eye functions to provide vision by transmitting and focusing light through a clear outer portion called the cornea, and further refining the focus of the image onto a retina by way of a crystalline lens. The quality of the focused image depends on many factors including the size and shape of the eye, and the transparency of the cornea and the lens.
The optical power of the eye is determined by the optical power of the cornea and the crystalline lens. In a normal, healthy eye, sharp images of distant objects are formed on the retina (emmetropia). In many eyes, images of distant objects are either formed in front of the retina because the eye is abnormally long or the cornea is abnormally steep (myopia), or formed in back of the retina because the eye is abnormally short or the cornea is abnormally flat (hyperopia).
Some people suffer from cataracts in which the crystalline lens undergoes a loss of transparency. In such cases, the crystalline lens can be removed and replaced with an intraocular lens (IOL). However, some intraocular lenses may still leave defects in a patient's non-distance eyesight.
Certain aspects of this disclosure are directed toward a method of manufacturing an intraocular lens. The method can include adding a first amount of a lens material to a first lens forming mold portion. The method can include positioning a mask with an aperture on a protruding pin of a positioning mold portion. The protruding pin can be configured to center the mask in the intraocular lens. The method can include joining the first lens forming mold portion and the positioning mold portion. The method can include partially curing the first amount of the lens material. Any of the mold features, intraocular lens or mask features, steps, or processes disclosed in this specification can be included in any embodiment.
In the above mentioned method aspect, the lens material can include an ultraviolet light absorber and a light-sensitive initiator. The initiator can be configured to cure the lens material when exposed to light having a wavelength outside the absorption spectrum of the ultraviolet light absorber. In certain aspects, the initiator can be configured to be activated by light having a wavelength in a range from about 380 nm to about 495 nm.
In any of the above mentioned method aspects, positioning the mask on the protruding pin can include positioning the mask adjacent to a shoulder portion of the protruding pin having a diameter larger than the aperture of the mask. The shoulder portion can be configured to control the depth of the mask in the intraocular lens.
In any of the above mentioned method aspects, joining the first lens forming mold portion and the positioning mold portion can cause lens material to flow into a space between a surface of the mask and an inner surface of the positioning mold portion from which the protruding pin extends so as to at least partially surround the mask with lens material on both of its sides.
In any of the above mentioned method aspects, partially curing the first amount of the lens material can include applying light to the first lens forming mold portion.
In any of the above mentioned method aspects, partially curing the first amount of the lens material can include curing the first amount of the lens material less than 50% of a full cure but to a sufficient degree that the mask remains with the first lens forming mold portion after removing the positioning mold portion.
In any of the above mentioned method aspects, the method can include cooling the first lens forming mold portion. The cooling process can help bias the mold set such that the lens material and mask remain in the first lens forming mold portion when the mold portions are separated. Other methods of biasing the mold set can include, but are not limited to, forming the first lens forming mold portion from a material that adheres to the lens material to a greater extent than the positioning mold portion material.
In any of the above mentioned method aspects, the method can include removing the positioning mold portion and joining the first lens forming mold portion and a second lens forming mold portion.
In any of the above mentioned method aspects, the method can include adding a second amount of the lens material to the second lens forming mold portion. In certain aspects, the method can include partially curing the second amount of the lens material less than 50% of a full cure by exposure to light. In certain aspects, the method can include, after partially curing the second amount of the lens material by exposure to light, thermally curing the second amount of the lens material.
In any of the above mentioned method aspects, the method can include polymerizing at least 99% of the first and second amounts of the lens material.
In any of the above mentioned method aspects, the lens material can be a hydrophobic material.
In any of the above mentioned method aspects, the method can include joining a haptic shield and the positioning mold portion such that the haptic shield prevents polymerization of the lens material in a haptic region.
Certain aspects of this disclosure are directed toward a mold set for manufacturing an intraocular lens having a mask suspended within the intraocular lens. The mold set can include a first lens forming mold portion configured to hold at least a portion of a lens material. The mold set can include a positioning mold portion configured to position the mask within the lens material. The positioning mold portion can be configured to mate with the first lens forming mold portion. The positioning mold portion can include a body portion and a protruding pin extending from the body portion. An end portion of the protruding pin can have a first diameter sized to correspond to an aperture in the mask. The protruding pin can be configured to control centration of the mask within the lens material. In certain aspects, the protruding pin can include a shoulder portion having a second diameter that is larger than the first diameter. The shoulder portion can be configured to control the depth of the mask within the lens material. Any of the mold features, intraocular lens or mask features, steps, or processes disclosed in this specification can be included in any embodiment.
In the above mentioned mold aspect, the length of the protruding pin can be sized such that the end portion of the protruding pin extends within 0 mm to 0.2 mm from the lens forming surface of the first lens forming mold portion when the positioning mold portion is joined with the first lens forming mold portion.
In any of the above mentioned mold aspects, a length of the protruding pin can be configured such that an optical zone of the intraocular lens is substantially free of the lens material when the first mold portion mates with the positioning mold portion.
In any of the above mentioned mold aspects, the second diameter of the shoulder portion can be about 50% of an outer diameter of the mask.
In any of the above mentioned mold aspects, the shoulder portion can be configured such that the lens material can flow between a surface of the mask and the body portion.
In any of the above mentioned mold aspects, the mold can include a second lens forming mold portion configured to hold another portion of the lens material and join with the first lens forming mold portion.
In any of the above mentioned mold aspects, the first lens forming mold portion can include a haptic region. In certain aspects, the mold can include a haptic shield positioned on the positioning mold portion such that the haptic shield blocks curing light from reaching the haptic region so as to prevent polymerization of the lens material within the haptic region.
For purposes of summarizing the disclosure, certain aspects, advantages and features of the inventions have been described herein. It is to be understood that not necessarily any or all such advantages are achieved in accordance with any particular embodiment of the inventions disclosed herein. No aspects of this disclosure are essential or indispensable.
As discussed herein, people who undergo intraocular lens (IOL) implantation surgery may still suffer from defects in their non-distance eyesight. One technique for treating such defects is by including a mask within the IOL that increases the patient's depth of focus. The intraocular implants of the embodiments described herein include a mask adapted to provide a small aperture for light to pass through to the retina to increase depth of focus. The light rays that pass through the mask within the IOL converge at a single focal point on the retina, while the light rays that would not converge at the single point on retina are blocked by the mask. This disclosure describes methods for manufacturing a lens, such as an IOL, having an embedded mask.
Several alternatives to fixed-focus IOLs have been developed, including multifocal IOLs and accommodating IOLs, that attempt to provide the ability to see clearly at both near and far distances. However, accommodating IOLs can be complex and some multifocal IOLs do not perform well at intermediate distances and cause glare, halos, and night vision difficulties associated with the presence of unfocused light. This limitation can force designers of multifocal optics to choose how much of the light is directed to each focal point, and to deal with the effects of the unfocused light that is always present in any image. In order to maximize acuity at the important distances of infinity (>6M) and 40 cm (normal reading distance), it is typical to provide little or no light focused at an intermediate distance, and as a result, visual acuity at these distances is poor. With a mask that includes an aperture to increase depth-of-focus, however, the intermediate vision of a patient can be improved significantly. For example, the defocus blur associated with the aperture can be less at intermediate distances than at near.
The intraocular lens and/or the lens body can be made from one or more materials. In certain embodiments, the intraocular lens material can include a hydrophobic material and/or a low-viscosity material. For example, in certain embodiments, the lens material can include a hydrophobic co-polymer such as those disclosed in U.S. Pat. No. 7,067,602, filed Jun. 27, 2006, which is hereby incorporated by reference in its entirety. In other embodiments, the intraocular lens and/or the lens body can comprise polymers (e.g. PMMA, PVDF, polypropylene, polycarbonate, PEEK, polyethylene, acrylic copolymers, polystyrene, PVC, polysulfone), hydrogels, or silicone.
In certain embodiments, the lens material can include an ultraviolet light absorber to provide protection for the eye. The intraocular lens body can be configured to permit less than about 10% of light transmission at 370 nm, less than about 5% of light transmission at 370 nm, less than about 1% of light transmission at 370 nm, or otherwise.
In certain embodiments, the intraocular lens can have a bi-convex design and/or can be configured to have a power range from at least about 12.5 diopter to less than or equal to about 30 diopter. In certain embodiments, the refractive index at 589 nm can be between about 1.481 and/or 1.487, between about 1.481 and/or 1.484, or otherwise. In certain embodiments, the refractive index at 546 nm can be between about 1.483 and/or 1.489, between about 1.482 and/or 1.484, or otherwise. In certain embodiments, the lens body can have a shore A hardness of at least about 90 and/or less than or equal to about 95. In certain embodiments, the lens body can have a shore A hardness of about 93.
Masks
A variety of variations of masks that can be positioned on or within the implant body are discussed herein, and also described in U.S. Pat. No. 7,628,810, U.S. Patent Publication No. 2006/0113054, and U.S. Patent Publication No. 2006/0265058, all of which are hereby incorporated by reference in their entirety.
The mask can have dimensions configured to function with the implant body to improve a patient's vision. For example, the thickness of the mask can vary depending on the location of the mask relative to the implant body. For example, if the mask is embedded within the implant body, the mask can have a thickness greater than zero and less than the thickness of the implant body. Alternatively, if the mask is coupled to a surface of the implant body, the mask may preferably have a thickness no greater than necessary to have desired opacity so that the mask does not add additional thickness to the intraocular lens.
The mask may have a constant thickness, as discussed below. However, in some embodiments, the thickness of the mask may vary between the inner periphery (near the aperture 2038a,b) and the outer periphery.
The annular region 2036a,b can be at least partially opaque or can be completely opaque. The degree of opacity of the annular region 2036a,b can prevent at least some or substantially all light from being transmitted through the mask 2034a,b. Opacity of the annular region 2036a,b can be achieved in any of several different ways.
For example, in some embodiments, the material used to make mask 2034a,b can be naturally opaque. In some embodiments, the material used to make the mask 2034a,b can be substantially clear, but treated with a dye or other pigmentation agent to render region 2036a,b substantially or completely opaque. In some embodiments, the surface of the mask 2034a,b can be treated physically or chemically (such as by etching) to alter the refractive and transmissive properties of the mask 2034a,b and make it less transmissive to light.
The material of the mask 2034a,b can be, for example, any polymeric material. Where the mask 2034a,b is applied to the intraocular implant, the material of the mask 2034a,b should be biocompatible. Examples of suitable materials for the mask 2034a,b can include, but are not limited to, highly fluorinated polymers, such as PVDF, hydrogels, or fibrous materials, such as a Dacron mesh.
In some embodiments, a photochromic material can be used as the mask or in addition to mask. Under bright light conditions, the photochromic material can darken thereby creating a mask and enhancing near vision. Under dim light conditions, the photochromic material can lighten, which allows more light to pass through to the retina. In certain embodiments, under dim light conditions, the photochromic material lightens to expose an optic of the intraocular implant. Further photochromic material details are disclosed in U.S. patent application Ser. No. 13/691,625, filed Nov. 30, 2012, which is hereby incorporated by reference in its entirety.
The mask can have different degrees of opacity. For example, the mask can block substantially all of visible light or a portion of visible light. The opacity of the mask can also vary in different regions of the mask. In certain embodiments, the opacity of the outer edge and/or the inner edge of the mask can be less than the central region of the mask. The opacity in different regions can transition abruptly or have a gradient transition. Additional examples of opacity transitions can be found in U.S. Pat. Nos. 5,662,706, 5,905,561 and 5,965,330, all of which are hereby incorporated by reference in their entirety.
Further mask details are disclosed in U.S. Pat. No. 4,976,732, issued Dec. 11, 1990, U.S. Pat. No. 7,628,810, issued Dec. 8, 2009, and in U.S. patent application Ser. No. 10/854,032, filed May 26, 2004, all of which are hereby incorporated by reference in their entirety.
In some embodiments, the mask 2100 can include a body 2104 that has an anterior surface 2108 and a posterior surface 2112. The body 2104 can be formed of any suitable material, including, but not limited to, at least one of an open cell foam material, an expanded solid material, and/or a substantially opaque material. In some embodiments, the material used to form the body 2104 can have relatively high water content. In some embodiments, the materials that can be used to form the body 2104 include polymers (e.g. PMMA, PVDF, polypropylene, polycarbonate, PEEK, polyethylene, acrylic copolymers (e.g., hydrophobic or hydrophilic), polystyrene, PVC, polysulfone), hydrogels, silicone, metals, metal alloys, or carbon (e.g., graphene, pure carbon).
In some embodiments, the mask 2100 can include a hole arrangement 2116. The hole arrangement 2116 can include a plurality of holes 2120. The holes 2120 are shown on only a portion of the mask 2100, but the holes 2120 can be located throughout the body 2104 in some embodiments. The mask 2100 can include an outer periphery 2124 that defines an outer edge of the body 2104. In some embodiments, the mask 2100 can include an aperture 2128 at least partially surrounded by the outer periphery 2124 and a non-transmissive portion 2132 located between the outer periphery 2124 and the aperture 2128.
The mask 2100 can be symmetrical, e.g., symmetrical about a mask axis 2136. In some embodiments, the outer periphery 2124 of the mask 2100 can be circular. The mask in general can have an outer diameter of at least about 3 mm and/or less than about 6 mm. In some embodiments, the mask is circular and can include a diameter of at least about 3 mm and/or less than or equal to about 4 mm. In some embodiments, the mask 2100 is circular and can include a diameter of about 3.2 mm.
In some embodiments, one of the anterior surface 2108 and the posterior surface 2112 of the body 2104 can be substantially planar. In some embodiments, very little or no uniform curvature can be measured across the planar surface. In some embodiments, both of the anterior and posterior surfaces 2108, 2112 can be substantially planar. In general, the thickness of the body 2104 of the mask 2100 can be within the range of from greater than zero to about 0.5 mm, about 1 micron to about 40 microns, in the range from about 5 microns to about 20 microns, or otherwise. In some embodiments, the body 2104 of the mask 2100 can include a thickness 2138 of at least about 5 microns and/or less than or equal to about 20 microns. In some embodiments, the body 2104 of the mask can include a thickness 2138 of at least about 5 microns and/or less than or equal to about 15 microns. In certain embodiments, the thickness 2138 can be about 15 microns, about 10 microns, about 8 microns, about 5 microns, or otherwise.
A substantially planar mask can have several advantages over a non-planar mask. For example, a substantially planar mask can be fabricated more easily than one that has to be formed to a particular curvature. In particular, the process steps involved in inducing curvature in the mask 2100 can be eliminated.
The aperture 2128 can be configured to transmit substantially all incident light along the mask axis 2136. The non-transmissive portion 2132 can surround at least a portion of the aperture 2128 and substantially prevent transmission of incident light thereon. As discussed in connection with the above masks, the aperture 2128 can be a through-hole in the body 2104 or a substantially light transmissive (e.g., transparent) portion thereof. The aperture 2128 of the mask 2100 can generally be defined within the outer periphery 2124 of the mask 2100. The aperture 2128 can take any of suitable configuration, such as those described above.
In some embodiments, the aperture 2128 can be substantially circular and can be substantially centered in the mask 2100. The size of the aperture 2128 can be any size that is effective to increase the depth of focus of an eye of a patient with presbyopia. In particular, the size of the aperture 2128 can be dependent on the location of the mask within the eye (e.g., distance from the retina). In some embodiments, the aperture 2128 can have a diameter of at least about 0.85 mm and/or less than or equal to about 2.2 mm. In certain embodiments, the diameter of the aperture 2128 is less than about 2 mm. In some embodiments, the diameter of the aperture is at least about 1.1 mm and/or less than or equal to about 1.6 mm. In some embodiments, the diameter of the aperture is at least about 1.3 mm and/or less than or equal to about 1.4 mm.
The non-transmissive portion 2132 can be configured to prevent transmission of visible light through the mask 2100. For example, in some embodiments, the non-transmissive portion 2132 can prevent transmission of substantially all or at least a portion of the spectrum of the incident visible light. In some embodiments, the non-transmissive portion 2132 can be configured to prevent transmission of substantially all visible light, e.g., radiant energy in the electromagnetic spectrum that is visible to the human eye. The non-transmissive portion 2132 can substantially prevent transmission of radiant energy outside the range visible to humans in some embodiments.
As discussed above, preventing transmission of light through the non-transmissive portion 2132 can decrease the amount of light that reaches the retina and the fovea that would not converge at the retina and fovea to form a sharp image. As discussed above, the size of the aperture 2128 is such that the light transmitted therethrough generally converges at the retina or fovea. Accordingly, a much sharper image can be presented to the retina than would otherwise be the case without the mask 2100.
In some embodiments, the non-transmissive portion 2132 can prevent transmission of at least about 90 percent of incident light. In some embodiments, the non-transmissive portion 2132 can prevent transmission of at least about 95 percent of all incident light. The non-transmissive portion 2132 of the mask 2100 can be configured to be substantially opaque to prevent the transmission of light.
In some embodiments, the non-transmissive portion 2132 can transmit no more than about 5% of incident visible light. In some embodiments, the non-transmissive portion 2132 can transmit no more than about 3% of incident visible light. In some embodiments, the non-transmissive portion 2132 can transmit no more than about 2% of incident visible light. In some embodiments, at least a portion of the body 2104 is configured to be opaque to more than 99 percent of the light incident thereon.
As discussed above, the non-transmissive portion 2132 may be configured to prevent transmission of light without absorbing the incident light. For example, the mask 2100 could be made reflective or could be made to interact with the light in a more complex manner, as discussed in U.S. Pat. No. 6,554,424, issued Apr. 29, 2003, which is hereby incorporated by reference in its entirety.
As discussed above, the mask 2100 can include a plurality of holes 2120. When the mask is formed embedded in the lens body, the lens body can extend at least partially through the holes, thereby creating a bond (e.g. material “bridge”) between the lens body on either side of the mask. Further disclosure regarding the material “bridge” can be found in U.S. Publication No. 2011/0040376, filed Aug. 13, 2010, which is hereby incorporated by reference in its entirety.
The holes 2120 of the mask 2100 shown in
In some embodiments, the mask 2100 can include an annular region near the outer periphery 2124 of the mask having no holes. In certain embodiments, there are no holes within 0.1 mm of the outer periphery 2124 of the mask 2100.
In some embodiments, the mask can include an annular region around the inner periphery of the mask having no holes. In certain embodiments, there are no holes within 0.1 mm of the aperture 2128.
In some embodiments, the holes 2120 each have a same diameter. In certain embodiments, the holes 2120 can include one or more different diameters. In some embodiments, the diameter of any single hole 2120 is at least about 0.01 mm and/or less than or equal to about 0.02 mm. In some embodiments, the diameter of the holes 2120 can include one or more of the following hole diameters: 0.010 mm, 0.013 mm, 0.016 mm, and/or 0.019 mm. In some embodiments, holes of different diameters are interspersed throughout at least a portion of the mask 2100. In some embodiments, the holes are interspersed at irregular locations throughout at least a portion of the mask 2100.
In some embodiments there are at least about 1000 holes and/or less than or equal to about 2000 holes. In some embodiments, there are at least about 1000 holes and/or less than or equal to about 1100 holes. In some embodiments, there are about 1040 holes. In some embodiments, there are an equal number of holes of each diameter. In some embodiments, the number of holes having each diameter is different.
In some embodiments, the holes are interspersed at irregular locations throughout at least a portion of the mask 2100. In some embodiments, holes of different diameters are evenly interspersed throughout at least a portion of the mask 2100. For example, the mask 2100 can include a plurality of non-overlapping hole regions. The sum of the surface area of the plurality of non-overlapping hole regions can equal to total surface area of the entire hole region of the mask. Each region of the plurality of regions can include a number of holes, each of the holes having a different diameter. The number of holes in each region can equal the number of different hole sizes in the entire hole region.
The first lens forming mold portion 4002 can include an interior lens forming surface 4004, an exterior surface 4006, a cavity 4024 for receiving lens material, and/or a haptic region 4026. The first lens forming mold portion 4002 can include an outer edge portion 4022 configured to join with the second lens forming mold portion and/or the positioning mold portion 4008.
The cavity 4024 can be sized for the dimensions of the intraocular lens. For example, the cavity 4024 can include a diameter of at least about 5 mm and/or less than or equal to about 6.5 mm. In certain embodiments, the cavity 4024 can include a diameter of about 6.0 mm. The diameter of the area including the cavity 4024 and the haptic region 4026 can be at least about 10 mm and/or less than or equal to about 20 mm. In certain embodiments, the diameter of the area including the cavity 4024 and the haptic region 4026 can be about 13.4 mm.
As shown in
The positioning mold portion 4008 can include an outer edge portion 4020 configured to join with the outer edge portion 4022 of the first lens forming mold portion 4002. The positioning mold portion 4008 can include an interior surface 4010 and an exterior surface 4012. The interior surface can include a protruding portion 4014, such as a protruding pin, extending from the interior surface 4010 of the positioning mold portion 4008. The protruding pin 4014 can include a shoulder portion 4016 with an enlarged diameter where the protruding pin 4014 extends from the interior surface 4010 of the positioning mold portion 4008. An annular mask 4028, such as those described herein, can be loaded onto the protruding pin 4014 before the positioning mold portion 4008 and the first lens forming mold portion 4002 are joined. The protruding pin 4014 can be transversely centered in the cavity 4024 to control the x-y position of the annular mask 4028 within the intraocular lens, while the shoulder portion 4016 can be configured to control the depth of the annular mask 4028 within the intraocular lens.
As shown in
The protruding pin 4014 can have a length such that an end portion of the protruding pin 4014 is within a distance X2 from the interior surface 4004 of the first lens forming mold portion 4002 when the positioning mold portion 4008 is joined to the first lens forming mold portion. In certain embodiments, X2 can be less than or equal to about 0.3 mm, less than or equal to about 0.2 mm, or less than or equal to about 0.1 mm. In certain embodiments X2 can be about 0.1 mm. In certain embodiments, the distance X1 from a base of the protruding pin 4014 to the interior surface 4004 of the first lens forming mold portion 4002 can be less than or equal to about 0.7 mm, less than or equal to about 0.6 mm, less than or equal to about 0.5 mm, or less than or equal to about 0.4 mm. In certain embodiments, the distance X1 can be about 0.5 mm. The length of the protruding pin 4014, from the shoulder portion 4016, can be equal to X1 less X2 (X1−X2). In certain embodiments, the length of the protruding pin 4014, from the shoulder portion 4016, can be at least about 0.2 mm and/or less than or equal to about 0.6 mm. In certain embodiments, the length of the protruding pin 4014, from the shoulder portion 4016, can be about 0.4 mm. It should be understood, however, that the specific dimensions of the protruding pin 4014 may depend upon various factors, including the design and optical power of the IOL.
The diameter of the shoulder portion 4016 can be larger than the inner diameter of the annular mask 4028, and can be configured to provide support for the annular mask 4028 and still allow a sufficient amount of lens material to flow behind the annular mask 4028. The lens material that flows behind the annular mask 4028 can polymerize and help stabilize the annular mask 4028 when the positioning mold portion 4008 is removed, as discussed further herein.
The shoulder portion 4016 can include a substantially uniform diameter or a varying diameter. As shown in
The length X3 of the shoulder portion 4016 can be configured to control the depth of the annular mask 4028 within the intraocular lens. In some embodiments, the length X3 is designed such that the annular mask 4028 is left substantially centered in the finished intraocular lens along the longitudinal axis of the lens. In some embodiments, the shoulder portion 4016 can include a length X3 of at least about 0.15 mm and/or less than or equal to about 0.35 mm. In certain embodiments, the length X3 can be about 0.25 mm. It should be understood, however, that the specific dimensions of the shoulder portion 4016 may depend upon various factors, including the design and optical power of the IOL.
The first lens forming mold portion 4002 and the positioning mold portion 4008 can be joined together by, for example, lying one mold portion atop the other mold portion. In some embodiments, the haptic shield 4018 can be configured to join the positioning mold portion 4008 or the first lens forming mold portion 4002. The haptic shield 4018 can be configured to block light from entering a haptic region 4026 of the mold during a photo curing stage of the manufacturing process. In some scenarios, if multiple doses of lens material are added to the mold and at least partially photo cured at different stages of the process, it may be desirable to block light from entering the haptic region during at least part of the curing process because later added doses of uncured lens material can cause previously polymerized lens material to swell and buckle. As shown in
In certain embodiments, the first amount of lens material can be equivalent to the amount of material necessary to completely fill the cavity 4024 and cause lens material to flow between the annular mask 4028 and the positioning mold portion 4008. In this way, the annular mask 4028 is at least partially embedded in lens material on both sides, which can aid in avoiding longitudinal movement of the annular mask 4028 when the first lens forming mold portion 4002 and the positioning mold portion 4008 are separated. If there is insufficient lens material to fill the cavity 4024, oxygen can be trapped in the mold, which can make it difficult to cure the material because oxygen can inhibit polymerization. In certain embodiments, the first amount of lens material can be at least about 100 microliters and/or less than or equal to about 150 microliters.
In some embodiments, the lens material can include an ultraviolet light absorber to protect the eye from ultraviolet light. The lens material can also include a light-sensitive initiator to allow the lens material to be photo cured by exposure to light. The light-sensitive initiator can include various biocompatible initiators, including, but not limited to, acylphosphine oxide initiators, such as Irgacure® 819. While the ultraviolet light absorption is a desirable feature of some embodiments of the intraocular lens, some light-sensitive initiators react to ultraviolet light. However, the presence of the ultraviolet light absorber could prevent such a light-sensitive initiator from being effective in a photo curing process. Thus, the initiator added to the lens material can be one that is activated when exposed to light having a wavelength outside the absorption spectrum of the ultraviolet light absorber (e.g., visible light range, violet-blue light range, or otherwise). In certain aspects, the initiator can be activated by light having a wavelength in a range from about 380 nm to about 495 nm. In certain aspects, the initiator can be activated by a light having a wavelength of about 420 nm. In certain aspects, the total amount of light initiator can be less than or equal to about 0.25% of the total amount of lens body material.
In block 6006, the first lens forming mold portion 4002 and the positioning mold portion 4008 can be joined together, for example, as shown in
In some embodiments, the haptic shield 4018 can be joined to the first lens forming mold portion 4002 and/or the positioning mold portion 4008 such that the haptic shield 4018 blocks light from reaching the haptic region 4026 and prevents polymerization of the lens material within the haptic region 4026 during certain curing stages of the fabrication process. In some embodiments, the haptic shield 4018 can join an outer edge portion 4020, 4022 of one or both of the mold portions 4002, 4008. The haptic shield 4018 can be positioned along the exterior surface 4012 of the positioning mold portion 4008 or the exterior surface 4006 of the first lens forming mold portion 4002. In certain embodiments the haptic shield 4018 can be configured to be embedded within one of the mold portions 4002, 4008 or can be positioned within the haptic region 4026.
After joining the mold portions 4002, 4008, the lens material can be at least partially cured (block 6010). For example, the lens material can be cured less than a full cure, e.g., at least about 10% and/or less than about 50% of a full monomer conversion. The lens material can be cured to a sufficient degree such that the annular mask 4028 remains with the first lens forming mold portion after removing the positioning mold portion. In addition, the partially cured lens material between the annular mask 4028 and the positioning mold portion 4008 can help hold the annular mask 4028 in place when the positioning mold portion 4008 is removed.
In some embodiments, the cure can be performed using a light cure, for example, using a 420 nm LED or any other suitable wavelength light described herein. Photo curing may be preferable to heat curing at this stage of the fabrication process because it can allow for greater control over the curing process. For example, a curing light can be turned on or off on command, which allows for fine control over the cure, whereas heat curing has more sluggish response times. In some embodiments, there can be a light intensity of at least about 0.5 milliwatts/cm2 and/or less than or equal to about 10 milliwatts/cm2. In some embodiments, the light intensity can be about 2 milliwatts/cm2. In some embodiments, the partial curing can take place for less than about 10 minutes, less than about 6 minutes, less than about 5 minutes, or otherwise.
In some scenarios, the light can be applied to the positioning mold portion 4008. However, if the annular mask 4028 includes an ultraviolet light absorber, the annular mask 4028 can prevent ultraviolet light from reaching the lens material, thereby inhibiting the partial curing process. In some embodiments, the mold set 4000 can be flipped over before the partial curing process or otherwise configured such that the light can be applied to the first lens forming mold portion 4002 (which can be made from a material that is substantially transparent to the curing light).
After partially curing the lens material, at least the first lens forming mold portion 4002 can be cooled (block 6012). The cooling process can increase lens material adhesion to the first lens forming mold portion 4002 and/or stiffen the partially cured lens material to help ensure that the lens material and annular mask 4028 stay with the first lens forming mold portion 4002 when the positioning mold portion 4008 and/or haptic shield 4018 are removed (block 6014). In some embodiments, the cooling process can be used to cool the first lens forming mold portion 4002 by at least 20 degrees. In certain embodiments, the cooling process can be carried out using a cryogenic fluid, such as liquid nitrogen.
In some embodiments, the mold portions 4002, 4008 can be separated using a machine-operated process to ensure that the mold portions 4002, 4008 are vertically displaced without disrupting the position of the annular mask 4028.
The materials of the mold set 4000 can also be configured to help cause the annular mask 4028 to stay with the first lens forming mold portion 4002 when the positioning mold portion 4002 is removed. For example, the first lens forming mold portion 4002 can include a material that adheres to the lens material to a greater extent, and the positioning mold portion 4008 can include a material that releases the lens material and/or annular mask 4028 more easily. In certain embodiments, the first lens forming mold portion 4002 can include a resin.
When the positioning mold portion 4008 is removed, the protruding pin 4014 can leave behind a void that is substantially free of any lens material. This void can be filled with uncured lens material when the second amount of lens material is added. The void left by the protruding pin 4014 is in the region of the optical axis of the lens and extends to a depth near or at the interior lens forming surface 4004 of the first lens forming mold portion 4002. Since the volume substantially surrounding the optical axis of the lens is filled with only the second amount of lens material, the finished optic can include a homogeneous optical material in the optical zone.
After removing the positioning mold portion 4008 and/or the haptic shield 4018, a second amount of lens material can be added to the first lens forming mold portion 4002 and/or the second lens forming mold portion (block 6016), and the first lens forming mold portion and the second lens forming mold portion can be joined together (6018). In some embodiments, the second amount of lens material is sufficient to completely fill the volume between the first and second lens forming mold portions. In certain embodiments, the second amount of lens material can be at least about 100 microliters and/or less than or equal to about 150 microliters. In certain embodiments, the second amount of lens material is about 150 microliters. After joining the first and second lens forming mold portions, the second amount of lens material can be allowed to diffuse through the partially cured first amount of lens material for a period of time (block 6020).
Following the diffusion period, the first and the second amount of lens material can be at least partially cured (block 6022). The first and the second amount of lens material can be cured at least about 10% and/or less than about a 50% of a full conversion of monomer to polymer. The partial curing process helps stabilize the position of the annular mask 4028 before the final cure. In some embodiments, the cure is performed using a light cure, for example, using a 420 nm LED or any other suitable wavelength light described herein. In some embodiments, the light intensity can be at least about 0.5 milliwatts/cm2 and/or less than or equal to about 10 milliwatts/cm2. In some embodiments, the light intensity can be about 2 milliwatts/cm2. In some embodiments, the light curing process can take place for less time than the first partial curing (block 6010). In some embodiments, the light intensity can be applied for less than about 5 minutes, less than about 3 minutes, or otherwise.
The final curing process can be carried out using thermal curing (block 6024). After the final cure, in some embodiments, the amount of leftover residual monomer can be less than 5% of the total amount of lens material, less than 1% of the total amount of lens material, less than 0.5% of the total amount of lens material, or otherwise, such that the residual monomer does not need to be extracted. In certain embodiments, only about 0.3% of residual monomer remains after the final cure.
After the final curing process, the intraocular lens can be hydrated with saline solution. As described above, the lens material can include a hydrophobic material. Hydrophobic lens materials can be useful because a finished lens may take up less water when hydrated in saline solution than lenses made of hydrophilic materials. If the lens body were to take up too much water, the lens body could swell and disrupt the positioning of the mask and/or damage the mask embedded within the intraocular lens. In certain embodiments, the intraocular lens material can include a water content of less than about 4%, or less than about 3%. In certain embodiments, the intraocular lens material can include a water content of about 2.5%.
In some embodiments, after the lens is removed from the mold set, it can be machined on either side or on both sides. For example, one side can be cut to the proper shape and then both sides can be polished. In some embodiments, the side of the lens to be cut is the side formed by the second lens forming mold portion.
Various embodiments have been described above. Although the invention has been described with reference to these specific embodiments, the descriptions are intended to be illustrative and are not intended to be limiting. Various modifications and applications may occur to those skilled in the art without departing from the true spirit and scope of the invention as defined in the appended claims.
This application is a continuation of U.S. patent application Ser. No. 15/815,017, filed on Nov. 16, 2017, which is a continuation of U.S. patent application Ser. No. 15/427,456, now U.S. Pat. No. 9,844,919, filed on Feb. 8, 2017, which is a continuation of U.S. patent application Ser. No. 15/133,139, now U.S. Pat. No. 9,573,328, filed on Apr. 19, 2016, which is a divisional of U.S. patent application Ser. No. 13/830,889, now U.S. Pat. No. 9,427,922, filed on Mar. 14, 2013, which is hereby incorporated by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
2350421 | Schoder et al. | Jun 1944 | A |
2470927 | Hale, Jr. | May 1949 | A |
3034403 | Neefe | May 1962 | A |
3270099 | Camp | Aug 1966 | A |
3458870 | Stone | Aug 1969 | A |
3578850 | Grant | May 1971 | A |
3776230 | Neefe | Dec 1973 | A |
3794414 | Wesley | Feb 1974 | A |
3877502 | Hunckler | Apr 1975 | A |
3996627 | Deeg et al. | Dec 1976 | A |
4010496 | Neefe | Mar 1977 | A |
4104338 | Guerrieri | Aug 1978 | A |
4116439 | Chavarria et al. | Sep 1978 | A |
4210391 | Cohen | Jul 1980 | A |
4298996 | Barnet | Nov 1981 | A |
4340283 | Cohen | Jul 1982 | A |
4402579 | Poler | Sep 1983 | A |
4423728 | Lieberman | Jan 1984 | A |
4435050 | Poler | Mar 1984 | A |
4450593 | Poler | May 1984 | A |
4505855 | Bruns et al. | Mar 1985 | A |
4563565 | Kampfer et al. | Jan 1986 | A |
4575373 | Johnson | Mar 1986 | A |
4596578 | Kelman | Jun 1986 | A |
4607617 | Choyce | Aug 1986 | A |
4624669 | Grendahl | Nov 1986 | A |
4639105 | Neefe | Jan 1987 | A |
4646720 | Peyman et al. | Mar 1987 | A |
4655774 | Choyce | Apr 1987 | A |
4665913 | Esperance, Jr. | May 1987 | A |
4669466 | L'Esperance | Jun 1987 | A |
4669834 | Richter | Jun 1987 | A |
4676790 | Kern | Jun 1987 | A |
4676791 | LeMaster et al. | Jun 1987 | A |
4678422 | York | Jul 1987 | A |
4701038 | Neefe | Oct 1987 | A |
4715858 | Lindstrom | Dec 1987 | A |
4767647 | Bree | Aug 1988 | A |
4795462 | Grendahl | Jan 1989 | A |
4798608 | Grendahl | Jan 1989 | A |
4799784 | Safir | Jan 1989 | A |
4799931 | Lindstrom | Jan 1989 | A |
4807623 | Lieberman | Feb 1989 | A |
4813955 | Achatz et al. | Mar 1989 | A |
4815690 | Shepherd | Mar 1989 | A |
4817789 | Paul | Apr 1989 | A |
4830855 | Stewart | May 1989 | A |
4842599 | Bronstein | Jun 1989 | A |
4842782 | Portney | Jun 1989 | A |
4851003 | Lindstrom | Jul 1989 | A |
4863466 | Schlegel | Sep 1989 | A |
4881860 | Kanazawa | Nov 1989 | A |
4903695 | Warner et al. | Feb 1990 | A |
4907586 | Bille et al. | Mar 1990 | A |
4928815 | Paul | May 1990 | A |
4955904 | Atebara et al. | Sep 1990 | A |
4976732 | Vorosmarthy | Dec 1990 | A |
4994080 | Shepard | Feb 1991 | A |
5013319 | Davis | May 1991 | A |
5030230 | White | Jul 1991 | A |
5034166 | Rawlings et al. | Jul 1991 | A |
5041133 | Sayano et al. | Aug 1991 | A |
5055602 | Melpolder | Oct 1991 | A |
5087015 | Galley | Feb 1992 | A |
5090955 | Simon | Feb 1992 | A |
5094521 | Jolson et al. | Mar 1992 | A |
5098443 | Parel et al. | Mar 1992 | A |
5108427 | Majercik et al. | Apr 1992 | A |
5112328 | Taboada et al. | May 1992 | A |
5120120 | Cohen | Jun 1992 | A |
5120121 | Rawlings et al. | Jun 1992 | A |
5137441 | Fogarty | Aug 1992 | A |
5147395 | Willis | Sep 1992 | A |
5171318 | Gibson et al. | Dec 1992 | A |
5185107 | Blake | Feb 1993 | A |
5188494 | Hatin | Feb 1993 | A |
5192316 | Ting | Mar 1993 | A |
5196026 | Barrett et al. | Mar 1993 | A |
5213749 | Huss et al. | May 1993 | A |
5260727 | Oksman et al. | Nov 1993 | A |
5266241 | Parekh | Nov 1993 | A |
5269795 | Arnott | Dec 1993 | A |
5269812 | White | Dec 1993 | A |
5274404 | Michael | Dec 1993 | A |
5288436 | Liu et al. | Feb 1994 | A |
5290892 | Namdaran et al. | Mar 1994 | A |
5292514 | Capecchi et al. | Mar 1994 | A |
5300116 | Chirila et al. | Apr 1994 | A |
5312330 | Klopotek | May 1994 | A |
5314439 | Sugita | May 1994 | A |
5314961 | Anton et al. | May 1994 | A |
5332802 | Kelman et al. | Jul 1994 | A |
5336261 | Barrett et al. | Aug 1994 | A |
5354331 | Schachar et al. | Oct 1994 | A |
5358520 | Patel | Oct 1994 | A |
5372580 | Simon et al. | Dec 1994 | A |
5391201 | Barrett et al. | Feb 1995 | A |
5441511 | Hanna | Aug 1995 | A |
5474548 | Knopp et al. | Dec 1995 | A |
5507740 | O'Donnell, Jr. | Apr 1996 | A |
5547468 | Simon et al. | Apr 1996 | A |
D375245 | Irving | Nov 1996 | S |
5578080 | McDonald | Nov 1996 | A |
5603774 | LeBoeuf et al. | Feb 1997 | A |
5607437 | Simon et al. | Mar 1997 | A |
5624456 | Hellenkamp | Apr 1997 | A |
5627613 | Kaneko | May 1997 | A |
5628794 | Lindstrom | May 1997 | A |
5628795 | Langerman | May 1997 | A |
5647865 | Swinger | Jul 1997 | A |
5653752 | Silvestrini et al. | Aug 1997 | A |
5662706 | Legerton et al. | Sep 1997 | A |
5674284 | Chang et al. | Oct 1997 | A |
5693268 | Widman et al. | Dec 1997 | A |
5697923 | Poler | Dec 1997 | A |
5702440 | Portney | Dec 1997 | A |
5708049 | Katagiri et al. | Jan 1998 | A |
5713957 | Steele et al. | Feb 1998 | A |
5722971 | Peyman | Mar 1998 | A |
5725575 | O'Donnell, Jr. | Mar 1998 | A |
5746558 | Nygren et al. | May 1998 | A |
5752967 | Kritzinger et al. | May 1998 | A |
5757458 | Miller et al. | May 1998 | A |
5769889 | Kelman | Jun 1998 | A |
5774202 | Abraham et al. | Jun 1998 | A |
5786883 | Miller et al. | Jul 1998 | A |
5824086 | Silvestrini | Oct 1998 | A |
5837156 | Cumming | Nov 1998 | A |
5843105 | Mathis et al. | Dec 1998 | A |
5864128 | Plesko | Jan 1999 | A |
5870167 | Knopp et al. | Feb 1999 | A |
5895610 | Chang et al. | Apr 1999 | A |
5905561 | Lee et al. | May 1999 | A |
5910537 | Feingold et al. | Jun 1999 | A |
5913898 | Feingold et al. | Jun 1999 | A |
5919185 | Peyman | Jul 1999 | A |
5925294 | Shibuya | Jul 1999 | A |
5964748 | Peyman | Oct 1999 | A |
5964776 | Peyman | Oct 1999 | A |
5965330 | Evans et al. | Oct 1999 | A |
5980040 | Xu et al. | Nov 1999 | A |
6017121 | Chateau et al. | Jan 2000 | A |
6063073 | Peyman | May 2000 | A |
6090141 | Lindstrom | Jul 2000 | A |
6102946 | Nigam | Aug 2000 | A |
6106553 | Feingold et al. | Aug 2000 | A |
6110166 | Juhasz et al. | Aug 2000 | A |
6138307 | McDonald | Oct 2000 | A |
6152959 | Portney | Nov 2000 | A |
6164777 | Li et al. | Dec 2000 | A |
6171336 | Sawusch | Jan 2001 | B1 |
6178593 | Carlson | Jan 2001 | B1 |
6197019 | Peyman | Mar 2001 | B1 |
6201036 | Fedorov et al. | Mar 2001 | B1 |
6203538 | Peyman | Mar 2001 | B1 |
6210401 | Lai | Apr 2001 | B1 |
6217571 | Peyman | Apr 2001 | B1 |
6217596 | Farah | Apr 2001 | B1 |
6221067 | Peyman | Apr 2001 | B1 |
6228113 | Kaufman | May 2001 | B1 |
6228114 | Lee | May 2001 | B1 |
6228115 | Hoffmann et al. | May 2001 | B1 |
6264648 | Peyman | Jul 2001 | B1 |
6277146 | Peyman et al. | Aug 2001 | B1 |
6280470 | Peyman | Aug 2001 | B1 |
6280471 | Peyman et al. | Aug 2001 | B1 |
6302877 | Ruiz | Oct 2001 | B1 |
6304390 | Takanashi | Oct 2001 | B1 |
6308590 | Berto | Oct 2001 | B1 |
6335190 | Zhou et al. | Jan 2002 | B1 |
6361560 | Nigam | Mar 2002 | B1 |
6376153 | Uchikawa et al. | Apr 2002 | B2 |
6387379 | Goldberg et al. | May 2002 | B1 |
6391230 | Sarbadhikari | May 2002 | B1 |
6416179 | Lieberman et al. | Jul 2002 | B1 |
6423093 | Hicks et al. | Jul 2002 | B1 |
6432246 | Blake | Aug 2002 | B1 |
6436092 | Peyman | Aug 2002 | B1 |
6458141 | Peyman | Oct 2002 | B1 |
6461384 | Hoffmann et al. | Oct 2002 | B1 |
6469844 | Iwase et al. | Oct 2002 | B1 |
6480346 | Funakoshi | Nov 2002 | B2 |
6491637 | Foster et al. | Dec 2002 | B2 |
6497700 | LaHaye | Dec 2002 | B1 |
6515006 | Horn | Feb 2003 | B2 |
6551307 | Peyman | Apr 2003 | B2 |
6554424 | Miller et al. | Apr 2003 | B1 |
6554860 | Hoffmann et al. | Apr 2003 | B2 |
6555103 | Leukel et al. | Apr 2003 | B2 |
6575573 | Lai et al. | Jun 2003 | B2 |
6581993 | Nigam | Jun 2003 | B2 |
6588902 | Isogai | Jul 2003 | B2 |
6589280 | Koziol | Jul 2003 | B1 |
6607527 | Ruiz et al. | Aug 2003 | B1 |
6613088 | Babizhayev | Sep 2003 | B1 |
6638304 | Azar | Oct 2003 | B2 |
6649722 | Rosenzweig et al. | Nov 2003 | B2 |
6655804 | Streibig | Dec 2003 | B2 |
6692126 | Xie et al. | Feb 2004 | B1 |
6702807 | Peyman | Mar 2004 | B2 |
6726322 | Andino et al. | Apr 2004 | B2 |
6740116 | Morcher | May 2004 | B2 |
6755858 | White | Jun 2004 | B1 |
6786926 | Peyman | Sep 2004 | B2 |
6811256 | Becherer et al. | Nov 2004 | B1 |
6855163 | Peyman | Feb 2005 | B2 |
6874886 | Miller et al. | Apr 2005 | B2 |
6899424 | Miller et al. | May 2005 | B2 |
6949093 | Peyman | Sep 2005 | B1 |
6951556 | Epstein | Oct 2005 | B2 |
6966648 | Miller et al. | Nov 2005 | B2 |
6989008 | Peyman | Jan 2006 | B2 |
6997428 | Andino | Feb 2006 | B1 |
7001374 | Peyman | Feb 2006 | B2 |
7008447 | Koziol | Mar 2006 | B2 |
7025455 | Roffman | Apr 2006 | B2 |
7061693 | Zalevsky | Jun 2006 | B2 |
7099057 | Parker et al. | Aug 2006 | B2 |
7276080 | Murakami et al. | Oct 2007 | B2 |
7287852 | Fiala | Oct 2007 | B2 |
7364674 | Hoover | Apr 2008 | B1 |
7399811 | Mentak et al. | Jul 2008 | B2 |
7404637 | Miller et al. | Jul 2008 | B2 |
7404638 | Miller et al. | Jul 2008 | B2 |
7446157 | Mentak et al. | Nov 2008 | B2 |
7455404 | Bandhauer et al. | Nov 2008 | B2 |
7455691 | Feingold et al. | Nov 2008 | B2 |
7462193 | Nagamoto | Dec 2008 | B2 |
7477452 | Tsuruma | Jan 2009 | B2 |
7491350 | Silvestrini | Jan 2009 | B2 |
7497866 | Perez | Mar 2009 | B2 |
7628810 | Christie et al. | Dec 2009 | B2 |
7641337 | Altmann | Jan 2010 | B2 |
7645299 | Koziol | Jan 2010 | B2 |
7745555 | Mentak et al. | Jun 2010 | B2 |
7842367 | Mentak | Nov 2010 | B2 |
7976577 | Silvestrini | Jul 2011 | B2 |
D645337 | Hsu et al. | Sep 2011 | S |
8043371 | Paul et al. | Oct 2011 | B2 |
8048972 | Mentak et al. | Nov 2011 | B2 |
8079706 | Silvestrini et al. | Dec 2011 | B2 |
D656526 | Christie et al. | Mar 2012 | S |
8157374 | Bandhauer et al. | Apr 2012 | B2 |
8241354 | Hong et al. | Aug 2012 | B2 |
8287592 | Silvestrini | Oct 2012 | B2 |
8343215 | Miller et al. | Jan 2013 | B2 |
D681086 | Christie et al. | Apr 2013 | S |
8420753 | Mentak et al. | Apr 2013 | B2 |
8460374 | Christie et al. | Jun 2013 | B2 |
8604098 | Boydston et al. | Dec 2013 | B2 |
8740978 | Weeber et al. | Jun 2014 | B2 |
8752958 | Miller et al. | Jun 2014 | B2 |
8633292 | Hu et al. | Jul 2014 | B2 |
8858624 | Christie et al. | Oct 2014 | B2 |
8864824 | Silvestrini et al. | Oct 2014 | B2 |
8955968 | Zalevsky et al. | Feb 2015 | B2 |
9005281 | Christie et al. | Apr 2015 | B2 |
9138142 | Christie et al. | Sep 2015 | B2 |
9204962 | Silvestrini | Dec 2015 | B2 |
9427311 | Christie et al. | Aug 2016 | B2 |
9427922 | Reboul et al. | Aug 2016 | B2 |
9492272 | Christie et al. | Nov 2016 | B2 |
9545303 | Vilupuru et al. | Jan 2017 | B2 |
9573328 | Reboul et al. | Feb 2017 | B2 |
9603704 | Silvestrini | Mar 2017 | B2 |
9757227 | Kushlin et al. | Sep 2017 | B2 |
9844919 | Reboul et al. | Dec 2017 | B2 |
9848979 | Vilupuru et al. | Dec 2017 | B2 |
9943403 | Webb et al. | Apr 2018 | B2 |
9987127 | Bogaert et al. | Jun 2018 | B2 |
10183453 | Reboul et al. | Jan 2019 | B2 |
20010027314 | Peyman | Oct 2001 | A1 |
20010034516 | Peyman | Oct 2001 | A1 |
20010050750 | Breger | Dec 2001 | A1 |
20020010510 | Silverstrini | Jan 2002 | A1 |
20020082288 | Horn | Jun 2002 | A1 |
20020120329 | Lang et al. | Aug 2002 | A1 |
20020167640 | Francis et al. | Nov 2002 | A1 |
20020196409 | Jani | Dec 2002 | A1 |
20030014042 | Juhasz et al. | Jan 2003 | A1 |
20030105521 | Perez | Jun 2003 | A1 |
20030135272 | Brady et al. | Jul 2003 | A1 |
20030149480 | Shadduck | Aug 2003 | A1 |
20030204258 | Graham et al. | Oct 2003 | A1 |
20030216763 | Patel | Nov 2003 | A1 |
20040019379 | Glick et al. | Jan 2004 | A1 |
20040056371 | Liao et al. | Mar 2004 | A1 |
20040068317 | Knight | Apr 2004 | A1 |
20040106929 | Masket | Jun 2004 | A1 |
20040140578 | Kelly et al. | Jul 2004 | A1 |
20050027355 | Murakami et al. | Feb 2005 | A1 |
20050046794 | Silvestrini et al. | Mar 2005 | A1 |
20050056954 | Devlin | Mar 2005 | A1 |
20050090895 | Peyman | Apr 2005 | A1 |
20050124983 | Frey et al. | Jun 2005 | A1 |
20050134793 | Roffman | Jun 2005 | A1 |
20050137703 | Chen | Jun 2005 | A1 |
20050143751 | Makker et al. | Jun 2005 | A1 |
20050182488 | Peyman | Aug 2005 | A1 |
20050187621 | Brady | Aug 2005 | A1 |
20050288784 | Peyman | Dec 2005 | A1 |
20060064077 | Peyman | Mar 2006 | A1 |
20060079959 | Christie et al. | Apr 2006 | A1 |
20060113054 | Silvestrini | Jun 2006 | A1 |
20060184243 | Yilmaz | Aug 2006 | A1 |
20060232665 | Schowengerdt et al. | Oct 2006 | A1 |
20060235428 | Silvestrini | Oct 2006 | A1 |
20060235514 | Silvestrini | Oct 2006 | A1 |
20060241751 | Marmo et al. | Oct 2006 | A1 |
20060265058 | Silvestrini | Nov 2006 | A1 |
20060268226 | Christie et al. | Nov 2006 | A1 |
20060268227 | Christie et al. | Nov 2006 | A1 |
20060268228 | Christie et al. | Nov 2006 | A1 |
20060268229 | Silvestrini et al. | Nov 2006 | A1 |
20060270946 | Silvestrini et al. | Nov 2006 | A1 |
20060271026 | Silvestrini et al. | Nov 2006 | A1 |
20060271178 | Christie et al. | Nov 2006 | A1 |
20060271179 | Christie et al. | Nov 2006 | A1 |
20060271180 | Christie et al. | Nov 2006 | A1 |
20060271181 | Christie et al. | Nov 2006 | A1 |
20060271182 | Christie et al. | Nov 2006 | A1 |
20060271183 | Christie et al. | Nov 2006 | A1 |
20060271184 | Silvestrini | Nov 2006 | A1 |
20060271185 | Silvestrini | Nov 2006 | A1 |
20060274264 | Christie et al. | Dec 2006 | A1 |
20060274265 | Christie et al. | Dec 2006 | A1 |
20070032866 | Portney | Feb 2007 | A1 |
20070091472 | Alkemper et al. | Apr 2007 | A1 |
20070092592 | Chiang | Apr 2007 | A1 |
20070129797 | Lang et al. | Jun 2007 | A1 |
20070225691 | Silvestrini et al. | Sep 2007 | A1 |
20080306587 | Your | Dec 2008 | A1 |
20090012505 | Chernyak | Jan 2009 | A1 |
20090021692 | Miller et al. | Jan 2009 | A1 |
20090287306 | Smith et al. | Jan 2009 | A1 |
20090059168 | Miller et al. | Mar 2009 | A1 |
20090069817 | Peyman | Mar 2009 | A1 |
20090171458 | Kellan et al. | Jul 2009 | A1 |
20090204207 | Blum et al. | Aug 2009 | A1 |
20090222086 | Lui et al. | Sep 2009 | A1 |
20090234448 | Weeber et al. | Sep 2009 | A1 |
20090306773 | Silvestrini et al. | Dec 2009 | A1 |
20100082100 | Mikawa | Apr 2010 | A1 |
20100127412 | Lake | May 2010 | A1 |
20100149618 | Sprague | Jun 2010 | A1 |
20100312336 | Hong et al. | Dec 2010 | A1 |
20110037184 | Shoji et al. | Feb 2011 | A1 |
20110040376 | Christie | Feb 2011 | A1 |
20110051080 | Bandhauer et al. | Mar 2011 | A1 |
20110125261 | Portney | May 2011 | A1 |
20110166652 | Bogaert et al. | Jul 2011 | A1 |
20110172675 | Danta et al. | Jul 2011 | A1 |
20110245919 | Pettit | Oct 2011 | A1 |
20110251685 | Chu | Oct 2011 | A1 |
20120203239 | Vukich et al. | Aug 2012 | A1 |
20120245683 | Christie et al. | Sep 2012 | A1 |
20120309761 | Chow et al. | Dec 2012 | A1 |
20120310338 | Christie et al. | Dec 2012 | A1 |
20130053953 | Silvestrini | Feb 2013 | A1 |
20130131795 | Miller et al. | May 2013 | A1 |
20130147072 | Bothe et al. | Jun 2013 | A1 |
20130238091 | Danta et al. | Sep 2013 | A1 |
20130289543 | Mordaunt | Oct 2013 | A1 |
20140131905 | Webb | May 2014 | A1 |
20140379078 | Trindade | Dec 2014 | A1 |
20150025627 | Christie et al. | Jan 2015 | A1 |
20150073549 | Webb et al. | Mar 2015 | A1 |
20150177422 | Liu et al. | Jun 2015 | A1 |
20150183173 | Linhardt et al. | Jul 2015 | A1 |
20150366658 | Christie et al. | Dec 2015 | A1 |
20160297107 | Shim et al. | Oct 2016 | A1 |
20170049560 | Cherne | Feb 2017 | A1 |
20170143477 | Christie et al. | May 2017 | A1 |
20170156850 | Silvestrini et al. | Jun 2017 | A1 |
20180125639 | Vilupuru et al. | May 2018 | A1 |
20180296322 | Webb et al. | Oct 2018 | A1 |
20180338826 | Link et al. | Nov 2018 | A1 |
20190076235 | Webb et al. | Mar 2019 | A1 |
20190076241 | Alarcon Heredia et al. | Mar 2019 | A1 |
20190193350 | Gu | Jun 2019 | A1 |
Number | Date | Country |
---|---|---|
2004201751 | May 2004 | AU |
1875895 | Dec 2006 | CN |
100368846 | Feb 2008 | CN |
101322663 | Dec 2008 | CN |
101341426 | Jul 2012 | CN |
4134320 | Apr 1992 | DE |
0165652 | Dec 1985 | EP |
0443094 | Aug 1991 | EP |
1173790 | Jan 2002 | EP |
1674049 | Jun 2006 | EP |
1548489 | Aug 2006 | EP |
2319457 | May 2011 | EP |
2243052 | Sep 2011 | EP |
2365379 | Sep 2011 | EP |
2455799 | May 2012 | EP |
2823789 | Jan 2015 | EP |
2364457 | Aug 2015 | EP |
2620687 | Mar 1989 | FR |
2649605 | Jan 1991 | FR |
1276003 | Jun 1972 | GB |
62-167343 | Jul 1987 | JP |
64-002644 | Jan 1989 | JP |
H02-7954 | Jan 1990 | JP |
04-158859 | Jun 1992 | JP |
06-509731 | Mar 1993 | JP |
H05-65340 | Sep 1993 | JP |
06-502782 | Mar 1994 | JP |
H07-067896 | Mar 1995 | JP |
07-265340 | Oct 1995 | JP |
08-103457 | Apr 1996 | JP |
H09-502542 | Mar 1997 | JP |
11-503657 | Aug 1997 | JP |
07-178125 | Jul 1998 | JP |
2000-047145 | Feb 2000 | JP |
2002-537895 | Nov 2002 | JP |
2003-502109 | Jan 2003 | JP |
2004-510199 | Apr 2004 | JP |
2004-538034 | Dec 2004 | JP |
2005-533576 | Nov 2005 | JP |
2007-516794 | Jun 2007 | JP |
2007-523720 | Aug 2007 | JP |
2008-506710 | Mar 2008 | JP |
S59-54527 | May 2008 | JP |
10-0335722 | May 2002 | KR |
2138837 | Sep 1999 | RU |
1380743 | Mar 1988 | SU |
WO 8705797 | Oct 1987 | WO |
WO 9503747 | Feb 1995 | WO |
WO 9508135 | Mar 1995 | WO |
WO 9635397 | Nov 1996 | WO |
WO 9848715 | Nov 1998 | WO |
WO 00025704 | May 2000 | WO |
WO 00038594 | Jul 2000 | WO |
WO 0051682 | Sep 2000 | WO |
WO 0052516 | Sep 2000 | WO |
WO 0070388 | Nov 2000 | WO |
WO 2001010641 | Feb 2001 | WO |
WO 0115779 | Mar 2001 | WO |
WO 0117460 | Mar 2001 | WO |
WO 0119364 | Mar 2001 | WO |
WO 01082815 | Nov 2001 | WO |
WO 02076320 | Oct 2002 | WO |
WO 02102241 | Dec 2002 | WO |
WO 03020177 | Mar 2003 | WO |
WO 03022168 | Mar 2003 | WO |
WO 03061518 | Jul 2003 | WO |
WO 2004014969 | Feb 2004 | WO |
WO 2004034917 | Apr 2004 | WO |
WO 2004105588 | Dec 2004 | WO |
WO 2004113959 | Dec 2004 | WO |
WO 2005082265 | Sep 2005 | WO |
WO 2006020638 | Feb 2006 | WO |
WO 2006047534 | May 2006 | WO |
WO 2006060380 | Jun 2006 | WO |
WO 2006069012 | Jun 2006 | WO |
WO 2006113377 | Oct 2006 | WO |
WO 2006113411 | Oct 2006 | WO |
WO 2006113563 | Oct 2006 | WO |
WO 2006113564 | Oct 2006 | WO |
WO 2007057734 | Oct 2007 | WO |
WO 2007133384 | Nov 2007 | WO |
WO 2007142981 | Dec 2007 | WO |
WO 2008036671 | Mar 2008 | WO |
WO 2008102096 | Aug 2008 | WO |
WO 2009050511 | Apr 2009 | WO |
WO 2009122409 | Oct 2009 | WO |
WO 2009140080 | Nov 2009 | WO |
WO 2009149060 | Dec 2009 | WO |
WO 2010059214 | May 2010 | WO |
WO 2011020074 | Feb 2011 | WO |
WO 2011020078 | Feb 2011 | WO |
WO 2011047076 | Apr 2011 | WO |
WO 2011069059 | Jun 2011 | WO |
WO 2011088107 | Jul 2011 | WO |
WO 2012170066 | Dec 2012 | WO |
WO 2013019871 | Feb 2013 | WO |
WO 2013082545 | Jun 2013 | WO |
WO 2013101793 | Jul 2013 | WO |
WO 2013112589 | Aug 2013 | WO |
WO 2013123265 | Aug 2013 | WO |
WO 2014054946 | Apr 2014 | WO |
WO 2014074610 | May 2014 | WO |
WO 2014158653 | Oct 2014 | WO |
WO 2014164056 | Oct 2014 | WO |
WO 2015021323 | Feb 2015 | WO |
WO 2015069927 | May 2015 | WO |
WO 2015073718 | May 2015 | WO |
WO 2016081493 | May 2016 | WO |
WO 2017062316 | Apr 2017 | WO |
WO 2017091520 | Jun 2017 | WO |
WO 2019010178 | Jan 2019 | WO |
Entry |
---|
Internet Archive Wayback Machine; Aniridia Implants; downloaded from https://web.archive.org/web/20110824062840/http://www.morcher.com/nc/produkte/aniridiaimplants.html (Archived Aug. 24, 2011; printed on Feb. 5, 2015). |
Guyton A.C., Textbook of Medical Physiology, 7th Edition, W.B. Saunders Company, Jan. 1986: Chapter 58, in 13 pages. |
International Search Report and Written Opinion for PCT/US2014/019118 dated Jul. 21, 2014 in 10 pages. |
Lu Xuequan, et al. “Radiation preparation and thermo-response swelling of interpenetrating polymer network hydrogel composed of PNIPAAm and PMMA”, Radiation Physics and Chemistry, vol. 57, Mar. 2000, pp. 477-480, XP002473596. |
Patel, C.K., et al. “Imaging the macula through a black occlusive intraocular lens”. Arch. Ophthalmol. Oct. 2010; 128(10):1374-1376. |
Yusuf, et al., “Inability to perform posterior segment monitoring by scanning laser ophthalmoscopy or optical coherence tomography with some occlusive intraocular lenses in clinical use”, J. Cataract Refract. Surg., Mar. 2012, 38: 513-518. |
Yusuf, et al., “Occlusive IOLs for Intractable Diplopia Demonstrate a Novel Near-Infrared Window of Transmission for SLO/OCT Imaging and Clinical Assessment”. Investigative Ophthalmology & Visual Science, May 2011, 52(6): 3737-3743. |
Number | Date | Country | |
---|---|---|---|
20190315081 A1 | Oct 2019 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 13830889 | Mar 2013 | US |
Child | 15133139 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15815017 | Nov 2017 | US |
Child | 16250392 | US | |
Parent | 15427456 | Feb 2017 | US |
Child | 15815017 | US | |
Parent | 15133139 | Apr 2016 | US |
Child | 15427456 | US |